Literature DB >> 32068527

Requirements for guinea pig cytomegalovirus tropism and antibody neutralization on placental amniotic sac cells.

K Yeon Choi1, Nadia S El-Hamdi1, Alistair McGregor1.   

Abstract

Congenital cytomegalovirus (cCMV) is a leading cause of birth defects. The guinea pig is the only small cCMV animal model. Guinea pig cytomegalovirus (GPCMV) encodes similar glycoprotein complexes to human CMV (HCMV) including gB and the gH-based pentamer complex (PC). In HCMV, both gB and PC are neutralizing antibody antigens. The relevance of GPCMV PC for virus tropism and vaccine target remains controversial. A novel guinea pig placental amniotic sac epithelial (GPASE) cell-line did not express viral cell receptor platelet derived growth factor receptor alpha (PDGFRA) and resulted in requirement for the PC for GPCMV infection unless PDGFRA was ectopically expressed. High titer anti-gB sera from a GPCMV gB vaccine study was evaluated for GPCMV neutralizing capability on GPASE cells in comparison to convalescent sera from GPCMV(PC+) or GPCMV(PC-) infected animals. Anti-gB sera neutralized fibroblast infection but was less effective compared to anti-GPCMV(PC-), which had antibodies to gH/gL. However, both anti-GPCMV(PC-) and anti-gB sera similarly had reduced neutralizing capability on GPASE and renal epithelial cells in comparison to anti-GPCMV(PC+) sera, which had additional antibodies to PC. Overall, results demonstrate the importance of the PC for GPCMV tropism to various cell types that lack PDGFRA expression and the limited ability of anti-gB sera to neutralize GPCMV on non-fibroblast cells despite the essential nature of gB glycoprotein.

Entities:  

Keywords:  CMV; Guinea pig cytomegalovirus; amniotic sac; congenital infection; glycoprotein gB; pentamer complex; placenta

Mesh:

Substances:

Year:  2020        PMID: 32068527      PMCID: PMC7414438          DOI: 10.1099/jgv.0.001394

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  57 in total

1.  Differences in the effects of mutations in GP131, a guinea pig cytomegalovirus homologue of pentameric complex component UL130, on macrophage and epithelial cell infection.

Authors:  Takuya Miura; Reina Makino; Kouhei Yamada; Miku Matsuura; Misaki Okumura; Souichi Yamada; Shinji Watanabe; Naoki Inoue
Journal:  J Gen Virol       Date:  2018-08-16       Impact factor: 3.891

Review 2.  Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy.

Authors:  Daniele Lilleri; Giuseppe Gerna
Journal:  Rev Med Virol       Date:  2016-12-23       Impact factor: 6.989

3.  Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Authors:  Elizabeth C Swanson; Pete Gillis; Nelmary Hernandez-Alvarado; Claudia Fernández-Alarcón; Megan Schmit; Jason C Zabeli; Felix Wussow; Don J Diamond; Mark R Schleiss
Journal:  Vaccine       Date:  2015-06-13       Impact factor: 3.641

4.  Cytomegalovirus UL128 homolog mutants that form a pentameric complex produce virus with impaired epithelial and trophoblast cell tropism and altered pathogenicity in the guinea pig.

Authors:  Stewart Coleman; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2017-06-23       Impact factor: 3.616

5.  Vaccine prevention of maternal cytomegalovirus infection.

Authors:  Robert F Pass; Changpin Zhang; Ashley Evans; Tina Simpson; William Andrews; Meei-Li Huang; Lawrence Corey; Janie Hill; Elizabeth Davis; Cynthia Flanigan; Gretchen Cloud
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

Review 6.  Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.

Authors:  Robert F Pass
Journal:  J Clin Virol       Date:  2009-07-31       Impact factor: 3.168

7.  Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.

Authors:  Xinle Cui; Zhouhong Cao; Shuishu Wang; Ronzo B Lee; Xiao Wang; Haruhiko Murata; Stuart P Adler; Michael A McVoy; Clifford M Snapper
Journal:  Vaccine       Date:  2018-08-03       Impact factor: 3.641

8.  Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection.

Authors:  Xiaohong Cui; Benjamin P Meza; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

9.  The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus.

Authors:  Isa Murrell; Carmen Bedford; Kristin Ladell; Kelly L Miners; David A Price; Peter Tomasec; Gavin W G Wilkinson; Richard J Stanton
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 12.779

10.  Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Daniel C Freed; Fengsheng Li; Zhiqiang An; Dai Wang; Tong-Ming Fu; Lenore Pereira
Journal:  Vaccines (Basel)       Date:  2019-09-29
View more
  8 in total

1.  A trimeric capable gB CMV vaccine provides limited protection against a highly cell associated and epithelial tropic strain of cytomegalovirus in guinea pigs.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  J Gen Virol       Date:  2021-03-17       Impact factor: 3.891

2.  Endothelial Cell Infection by Guinea Pig Cytomegalovirus Is a Lytic or Persistent Infection Depending on Tissue Origin but Requires Viral Pentamer Complex and pp65 Tegument Protein.

Authors:  K Yeon Choi; Nadia El-Hamdi; Alistair McGregor
Journal:  J Virol       Date:  2022-08-24       Impact factor: 6.549

3.  Cross Strain Protection against Cytomegalovirus Reduces DISC Vaccine Efficacy against CMV in the Guinea Pig Model.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  Viruses       Date:  2022-04-06       Impact factor: 5.818

4.  Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.

Authors:  Nadia S El-Hamdi; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2020-06-11       Impact factor: 3.616

5.  Guinea pig cytomegalovirus protective T cell antigen GP83 is a functional pp65 homolog for innate immune evasion and pentamer dependent virus tropism.

Authors:  K Yeon Choi; Nadia El-Hamdi; Julia Hornig; Alistair McGregor
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

6.  Convalescent Immunity to Guinea Pig Cytomegalovirus Induces Limited Cross Strain Protection against Re-Infection but High-Level Protection against Congenital Disease.

Authors:  K Yeon Choi; Nadia S El-Hamdi; Alistair McGregor
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

7.  Limited replication of human cytomegalovirus in a trophoblast cell line.

Authors:  Kadeem Hyde; Nowshin Sultana; Andy C Tran; Narina Bileckaja; Claire L Donald; Alain Kohl; Richard J Stanton; Blair L Strang
Journal:  J Gen Virol       Date:  2021-11       Impact factor: 5.141

8.  A Fully Protective Congenital CMV Vaccine Requires Neutralizing Antibodies to Viral Pentamer and gB Glycoprotein Complexes but a pp65 T-Cell Response Is Not Necessary.

Authors:  K Yeon Choi; Alistair McGregor
Journal:  Viruses       Date:  2021-07-27       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.